You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,575,923

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,575,923

Title:	CD19xCD3 specific polypeptides and uses thereof
Abstract:	Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
Inventor(s):	Dorken; Bernd (Berlin, DE), Riethmuller; Gert (Munich, DE), Kufer; Peter (Moosburg, DE), Lutterbuse; Ralf (Munich, DE), Bargou; Ralf (Berlin, DE), Loffler; Anja (Finowfurt/Eichhorst, DE)
Assignee:	Micromet AG (Munich, DE)
Application Number:	11/418,058
Patent Claims:	1. A polynucleotide which upon expression encodes a single-chain multi-functional polypeptide comprising (a) a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD 19 antigen; and (b) a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen; wherein said domains are arranged in the order V.sub.LCD19-V.sub.H-CD19-V.sub.HCD3-V.sub.LCD3. 2. A vector comprising the polynucleotide of claim 1. 3. An isolated host cell transfected with the polynucleotide of claim 1. 4. A An isolated host cell transfected with the vector of claim 2.

Details for Patent 7,575,923

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	BLINCYTO	blinatumomab	For Injection	125557	12/03/2014	⤷ Try a Trial	2018-04-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,575,923

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Austria	244758	⤷ Try a Trial
Australia	4135299	⤷ Try a Trial
Australia	761587	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.